Literature DB >> 11224226

An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus-maze.

J.C. Cole1, R.J. Rodgers.   

Abstract

The effects of chlordiazepoxide (2.5-15.0mg/kg), a full benzodiazepine receptor agonist, and bretazenil (5.0-30.0mg/kg), a partial benzodiazepine receptor agonist, were examined in the murine elevated plus-maze paradigm. Behaviours recorded comprised the traditional indices of anxiety as well as a number of ethologically derived measures. Results show that chlordiazepoxide (10-15mg/kg) and bretazenil (5-30mg/kg) not only decreased traditional indices of anxiety but also reduced risk assessment behaviours such as head-dipping and stretch attend postures from secure areas of the maze. Both compounds produced these effects without adversely affecting general activity levels. While traditional indices of anxiety did not clearly discriminate between the two compounds, some differences were apparent on the ethological measures. The dose-response curves for bretazenil were generally shallower than those for chlordiazepoxide, confirming its partial agonist profile. Together, these data support the view that benzodiazepine receptor partial agonists may have utility in the management of human anxiety disorders.

Entities:  

Year:  1993        PMID: 11224226

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  18 in total

Review 1.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

2.  GABAA Receptor Subtypes and the Reinforcing Effects of Benzodiazepines in Remifentanil-Experienced Rhesus Monkeys.

Authors:  Lais F Berro; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2020-05-25       Impact factor: 4.492

3.  The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (omega 1) selective, benzodiazepine receptor ligands.

Authors:  G Griebel; D J Sanger; G Perrault
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

4.  Involvement of 2-arachidonoylglycerol signaling in social challenge responding of male CD1 mice.

Authors:  Mano Aliczki; Zoltan Kristof Varga; Zoltan Balogh; Jozsef Haller
Journal:  Psychopharmacology (Berl)       Date:  2014-12-31       Impact factor: 4.530

5.  Changes in mouse cognition and hippocampal gene expression observed in a mild physical- and blast-traumatic brain injury.

Authors:  David Tweedie; Lital Rachmany; Vardit Rubovitch; Yongqing Zhang; Kevin G Becker; Evelyn Perez; Barry J Hoffer; Chaim G Pick; Nigel H Greig
Journal:  Neurobiol Dis       Date:  2013-02-27       Impact factor: 5.996

6.  The multifaceted effects of oral administration of methylphenidate in juvenile rats: anxiety, activity, and attention.

Authors:  Ning Zhu; Jeremy Weedon; Diana L Dow-Edwards
Journal:  Eur Neuropsychopharmacol       Date:  2010-01-18       Impact factor: 4.600

7.  Differential behavioral and molecular alterations upon protracted abstinence from cocaine versus morphine, nicotine, THC and alcohol.

Authors:  Jérôme A J Becker; Brigitte L Kieffer; Julie Le Merrer
Journal:  Addict Biol       Date:  2016-04-28       Impact factor: 4.280

8.  Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol.

Authors:  J C Cole; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

9.  The ambivalent behaviour "stretched approach posture" in the rat as a paradigm to characterize anxiolytic drugs.

Authors:  H E Molewijk; A M van der Poel; B Olivier
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

10.  Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice.

Authors:  N J Johnson; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.